



Progress and Characterization of Pramipexole Extended-Release Tablets

B. Reshma*, A. Priyanka, G. Sreekanth

¹Department of Pharmaceutics, Jangaon institute of pharmaceutical sciences, Jangaon-506167, Telangana, India.**Corresponding Author:** B. Reshma, Department of Pharmaceutics, Jangaon institute of pharmaceutical sciences, Jangaon-506167, Telangana, India.**Received Date:** November 20, 2021; **Accepted Date:** December 16, 2021; **Published Date:** December 20, 2021**Citation** B. Reshma, A. Priyanka, G. Sreekanth, Progress and Characterization of Pramipexole Extended-Release Tablets, J.Clinical and Medical Case Reports and Reviews. V(1)I(1)**Copyright:** © 2021 B. Reshma, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Pramipexole dihydrochloride monohydrate is an antiparkinson's agent which is known as dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g. bromocriptine or pergolide. Pramipexole is designated chemically as (S)-2-Amino-4, 5, 6, and 7-tetrahydro-6-(propylamino) benzothiazole and has the molecular formula $C_{10}H_{17}N_3S$. It comes under class I of Biopharmaceutical Classification System. The purpose of this study was to develop and evaluate pramipexole dihydrochloride monohydrate extended release tablets by wet granulation method using different proportions of polymers and binder. Pre-formulation studies were done initially and the results were found to be within the limits. All the mentioned batches were prepared and granules were evaluated for pre-compression parameters such as loss on drying, bulk density, tapped density and compressibility index. Tablets were evaluated for weight variation, thickness, hardness, friability; disintegration time and assay were found to be within the limits. In vitro dissolutions were performed with 0.05M 6.8 PH phosphate buffer and effect of various polymers were explored. Final selection of formulation was based on dissolution profile, from dissolution studies formulation 9 showed 80% drug release within 20 hours, so it will be compared with innovator. Similarity and difference factors which revealed that formulation (F 9) containing HPMC K 200, Eudragit L100 and binder are most successful as it exhibited in vitro drug release that matched with innovator product. In vitro drug release profile reveals that with increased concentration of Eudragit L 100. Accelerated stability studies were performed for the optimized batch which indicated that there were no changes in drug content and in vitro dissolution.

Keywords: Extended Release; antiparkinson's agent; drug delivery system

Introduction

1.1 Conception-

The challenge of targeting medicines specifically to the colonic region of the gastrointestinal tract is one that has been embraced by scientists over the once two decades. The colon has lately been accepted as a decreasingly important point for medicine delivery. Among all the routes of medicine administration that have been explored for the development of controlled release systems the oral route has in far achieved the utmost attention and success. It's to the ease of administration as well as to the fact that gastrointestinal physiology offers further inflexibility in lozenge form design than utmost other routes¹.

The scientific framework needed for development of a successful oral controlled medicine delivery consists of an understanding the furrowing aspects-

The physicochemical characteristics of the medicine. Applicable GI deconstruction and physiology.

Lozenge form characteristics.

The factors to be considered in the design of colon-specific medicine delivery system deconstruction and physiology of colon pH in the colon

Gastrointestinal conveyance

Colonic micro foliage deconstruction and physiology of colon

The GI tract is divided into stomach, small intestine, and large intestine. The large intestine extending from ileocaecal junction to the anus is divided into three main corridors. These are the colon, the rectum and the anal conduit. The colon is divided into caecum, thrusting colon, hepatic flexure, transverse colon, the splenic flexure, descending colon and the sigmoid colon. It's about 1.5 m long, the transverse colon being the longest and most mobile part and has an average periphery of about 6.5 cm, although it varies in periphery from roughly 9 cm in the caecum to 2 cm in the sigmoid colon.

2. Review of Literature

4Morishita M et al.,⁵⁶ has estimated the utility of colon targeted (1 acid) and EPA (eicosapentanoic acid) as a new diabetic specific that promote natural glucagon-like peptide-1 (GLP-1) stashing. The end of this study was to estimate the goods of the long chain adipose acids DHA and EPA on blood glucose situations, tube insulin and GLP-1 attention. In addition, point-specific differences in these goods were determined using several intestinal parts, stomach, jejunum and colon.

Sanket D Gandhi et al.,⁵⁷ has formulated and estimated the colon targeted tablets of secnidazole for the treatment of amoebiasis. The colon as a point for medicine delivery offers distinct advantages on account of a near neutral pH a much longer conveyance time, fairly low proteolytic enzyme exertion and a much lesser responsiveness to immersion enhancers. The formulated tablets were estimated for hardness, frangibility, weight variation, medicine content, in-vitro and stability study.

Kishor sahebrao salunkhe et al.,⁵⁸ has formulated and estimated the dextrin matrix tablets of ibuprofen for colon specific medicine delivery. The formulated matrix tablets were estimated by different IPQC tests, content uniformity and in-vitro medicine release study. The results of in-vitro study indicate the matrix tablets containing dextrin as carrier and ethyl cellulose as binder are most suitable to deliver the medicine specifically in colonic region as compared to matrix tablets of dextrin with other binder systems.



SI. No	Materials	Source
1	Pramipexole diHCl monohydrate	A gift sample from Eros Pharma, Bangalore CFL Pharma, Goa
2	Lactose monohydrate	Kelco Pharma
3	Microcrystalline cellulose PH 101	Rohm Pharma. Bombay
4	Eudragit L 100	Rohm Pharma. Bombay
5	HPMC E 3LV	SD Fine Chem., Bombay
6	Povidone K 90	SD Fine Chem., Bombay
7	HPMC K4M	SD Fine Chem., Bombay
8	HPMC K 200	SD Fine Chem., Bombay
9	MCC 112	SD Fine Chem., Bombay
10	Aerosil 200	SD Fine Chem., Bombay
11	Stearic acid	SD Fine hem., Bombay

Table 1: List of chemicals used with their grades and supplier names

Kishore G et al.,⁵⁹ has developed and estimated the colon targeted tablets of praziquantel and its β - cyclodextrin complex to treat schistosomiasis. They planned to ameliorate the solubility of praziquantel by forming addition complex with β - CD. Different phrasings were prepared by changing the attention of matrix carriers and β - CD. phrasings containing xanthum goo and guar goo showed maximum medicine release in colonic terrain. These phrasings were perplexed with β - CD. After complexation of praziquantel with β - CD, praziquantel dissolution is significantly increased in colonic terrain.

3. Ideal

Need for the study

The end of the present exploration work was to develop matrix tablets of Metformin HCL targeted to colon.


The delivery of medicines to colon for systemic action or a original effect is precious in a variety of circumstances. These include the topical treatment of conditions similar as ulcerative colitis, Chron's complaint, perverse colon pattern, contagious complaint, colon cancer and the eventuality for the oral delivery of peptides and other labile medicines. Targeting of medicines to the colon via oral route can be achieved by different approaches including different expression system. For which the medicine release is controlled by different pH conditions, conveyance time and microbial foliage.

Metformin HCL is a BCS class- III (largely answerable- unwell passable) biguanide outgrowth that has been used worldwide for the treatment of type- II diabetes. In malignancy of its favorable clinical response chronic remedy with Metformin HCL suffers from

certain specific problems of which, the most prominent being the high cure (1.5-2.0 g/ day), partial life is about 1.5-3.5 hours, low bioavailability (60) and high prevalence of GI side goods (30 cases). The situation is complicated further with drop in immersion of medicine with food that detainments tmax by over to 35 mins.

Colon targeted medicine delivery systems are developed to increase the bioavailability of medicines since colon is composed of large quantum of lymphoid towel the medicine by passes the first-pass metabolism and enters into the systemic rotation. still Metformin HCL cannot cross the colonic epithelial subcaste since it belongs to BCS class- III. In order to increase the bioavailability of Metformin HCL saturation enhancers like succinic acid is used. therefore, it improves bioavailability there by frequence of dosing is reduced, minimize the GI side goods and improves the patient compliance through CDDS.

4. Medicine Profile



Chemical Name, 1,1- dimethylbiguanide hydrochloride

Empirical Formula C₄H₁₁N₅. HCl

Molecular Weight 165.62

Melting point 222°C to 226°C

order Hypoglycemic agent

Cure 0.5 to 3g daily in divided doses

pKa 12.4

Description White, crystalline grease paint, hygroscopic.

5. Polymers Outline

Hydroxy Propyl Methyl Cellulose 91,92

Antonyms Cellulose, Hydroxy propyl methyl ether; HPMC; Propylene glycol Ether; Methocel; Pharmacoat, Methyl cellulose, Methyl hydroxy propyl cellulose.

Chemical Name Cellulose, 2- hydroxypropyl methyl ether.

Molecular Weight roughly, 000

Category Coating agent, film-former, stabilizing agent, suspending agent, tablet binder and density- adding agent.

Apparent viscosity 0.25-0.75 g/ cm³

Description Hydroxy propyl methyl cellulose is an odourless, tasteless, white or delicate-white coloured stringy or grainy grease paint.

Solubility Soluble in cold water, undissolvable in chloroform, ethanol and ether, but answerable in fusions of ethanol or methanol and Dichloromethane.

Density

The density of the polymer is in the range from 75- 140 of the declared value.

Stability and storehouse It's a stable material although it's hygroscopic after drying. Increase in temperature reduces the density of results. It undergoes a reversible response to gel metamorphosis upon heating and cooling independently. The grease paint should be stored in a well-unrestricted vessel in a cool and dry place.

Incompatibility Extreme pH conditions, oxidizing accoutrements.

Experimental Studies

Preformulation Studies

Description Visual examination of medicine was done and description as per specification was checked.

Melting point

Melting point of medicine was determined by capillary system in triplet. The melting point was set up to be in the range of 222°C- 226°C.

Solubility in different dissolution media

Redundant quantum of the medicine is added to 100 ml distilled water, 100 ml phosphate buffer pH 7.4 (intestine), 100 ml phosphate buffer pH 6.8 (colon). After adding maximum quantum of the medicine shake each volumetric beaker in a shaker for further than 12 hrs for maximum achromatism of the result. also 5 ml of result was removed from each beaker and dilution was made as needed. Absorbance was taken at 233 nm in UV-Visible spectrophotometer.

Preparation of 1.2 pH phosphate buffer result

Place 250 ml of 0.2 M potassium chloride result (14.911



g/ litre of distilled water) in a 1 Litre volumetric beaker add 425.0 ml of 0.2 M hydrochloric acid and sufficient volume of distilled water to produce 1000 ml blend it well.

Preparation of 6.8 pH phosphate buffer result
gm of monobasic potassium phosphate was counted and adulterated up to 1000 ml to get stock result of monobasic potassium phosphate. 8gm Sodium hydroxide was counted and adulterated up to 1000 ml to get 0.2 M sodium hydroxide result. 50ml of the monobasic potassium phosphate result was taken from the stock result in a 200- ml volumetric beaker and 22.4 ml of sodium hydroxide result from stock result of 0.2 M sodium hydroxide result was added and also water was added to make up the volume.

Methodology

5.1 Materials Used:

Results and Conversations

Standard estimation of Metformin HCl in 1.2 pH buffer
The absorbance was measured in a UV spectrophotometer at 233 nm against 1.2 pH buffer

7.1. Preformulation Studies

In the Preformulation studies, it was set up that the estimation of Pramipexole dihydrochloride monohydrate by UV Spectrophotometry system at λ maximum 260 nm in distilled water showed reproducibility and this system was employed in the study. The correlation measure for the standard was set up to be 0.9996, at the attention range, 10- 60 mcg/ ml and the regression equation generated was $Y = 0.500x - 0.015x$. medicine – excipients compatibility studies were carried out and no change was observed medicine – Excipient compatibility Studies

As described in the methodology section the FT- IR studies were carried out for pure medicine alone and on with polymers. The results are epitomized as follows. An FT- IR diagram of pure Pramipexole dihydrochloride monohydrate is shown in the Figure 3 and medicine and excipients compatibility are listed in the Table 6. also, FT- IR gamuts of Pramipexole dihydrochloride monohydrate in combination with polymers are shown in numbers 4 to 8. These peaks weren't affected and prominently observed in FT- IR gamuts given in numbers 4 to 8. This indicates that there's no commerce between Pramipexole dihydrochloride monohydrate and polymers and the medicine was compatible with the expression factors.

6. Summary

Targeting of medicine to the colon is recognised to have several remedial advantages because colon is rich in lymphoid tissue, uptake of antigens in to the mast cells of the colonic mucosa produce rapid-fire product of antibodies and therefore helps in effective vaccine delivery. The colon has longer retention time and appears largely responsive to an agent that enhances the immersion of inadequately absorbed medicines. immersion of medicine moles from the colon like other regions of GIT is a result of a complex series of events. Successful colonic uptake of a medicine species bear both enzymatic stability and has to transport from the mucosal face to the venous and or lymphatic capillaries located in the sub mucosa. The colonic epithelial permeability is inadequate to allow for the transport rate needed for a remedial delivery. also the co-administration of an immersion enhancing agent offers a implicit means of over coming this hedge substantially through the use of chemical enhancers like chelating agents, surfactant and dicarboxylic acids(succinic acid, lauric acid etc)

The delivery of medicines to colon for systemic action or a original effect is precious in a variety of circumstances. These include the topical treatment of conditions similar as ulcerative colitis, Chron's complaint, perverse colon pattern, contagious complaint, colon cancer and the eventuality for the oral delivery of peptides and other labile medicines. Targeting of medicines to the colon via oral route can be achieved by different approaches including different expression system. For which the medicine release is controlled by different pH conditions, conveyance time and microbial foliage.

Metformin HCL was chosen as a model medicine. It's a BCS class-III (largely answerable- unwell passable) biguanide outgrowth that has been used worldwide for the treatment of type- II diabetes. In malignancy of its favourable clinical response chronic remedy with Metformin HCL suffers from certain specific problems of which, the

most prominent being the high cure (1.5-2.0 g/ day), partial life is about 1.5-3.5 hours, low bioavailability (60) and high prevalence of GI side goods (30 cases). The situation is complicated further with drop in immersion of medicine with food that detainments t-max by over to 35 mins'

References:

1. [Juliano RL. Drug Delivery Systems. Oxford University Press. New York. 1980.](#)
2. [Robinson JR. Sustained and Controlled Drug Delivery System: Marcel Dekker Inc-New York and Basel: 1978.](#)
3. [Yie W.Chien. Novel Drug Delivery Systems 1992 Marcel Dekker Inc New York 2nd edition: 1-2.](#)
4. [Gennaro AR. The Science and Practice of Pharmacy 1995: 19th edition \(2\): 1662.](#)
5. [Peter G.Welling. Drug Develop & Ind. Pharma., 9\(7\), 1188, \(1983\).](#)
6. [Robinson JR and Lee HL. Controlled Drug Delivery fundamentals and application 1987; Marcel Dekker Inc New York, 2nd edition: 373.](#)
7. [Herbert A. Liberman and Leon Lachman. Pharmaceutical Dosage Forms Tablets: Marcel Dekker Inc New York, Vol.3: 9-10](#)
8. [Dahkuri A et al., J.Pharma.Sci. 1978; 67:357.](#)
9. [Krishnaiah YSR and Patross. Pharma Times 2001; 33:16-18.](#)
10. [Lachman L, Liberman HA and Kanig JL. The theory and practice of industrial Pharmacy 1991; 3rd edition: 296, 299, 430.](#)
11. [Bhalla HL and Raj C Piyush. Indian drugs 1991; 28\(11\): 519-522.](#)
12. [Brahmankar DM et al., Cellulose matrices for controlled release of ketorolac tromethamine. Indian drugs 1996; 33\(3\): 120-123.](#)



Ready to submit your research? Choose Alcrut and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Alcrut, research is always in progress.

Learn more: <https://alcrut.com/en/journals/journal-of-clinical-and-medical-case-reports-and-reviews>



is work is licensed under creative
der creative commons attribution 4.0 To
submit your article Click Here: [Submit
manuscript](#)

